Notably, studies have reported diarrhea in 27%-54% of cancer patients undergoing cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitor therapy, while colitis occurred in 8%-22% of these patients [12]. Here, CTLA4 is linked to colitis.